Lichtstrasse 35
Basel 4056
Switzerland
41 61 324 1111
https://www.novartis.com
Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 76.057
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Dr. Vasant Narasimhan M.D. | Chief Executive Officer | 8,05M | N/D | 1976 |
Mr. Harry Kirsch | Chief Financial Officer | 4,01M | N/D | 1965 |
Mr. Victor Bulto | President of US | 3,3M | N/D | 1978 |
Dr. Patrick Horber M.D. | President of International | 7,35M | N/D | 1970 |
Dr. Steffen Lang Ph.D. | President of Operations | 2,35M | N/D | 1967 |
Paul Penepent | Head of Group Financial Reporting and Accounting | N/D | N/D | N/D |
Dr. Klaus Moosmayer Ph.D. | Chief Ethics, Risk & Compliance Officer | 1,56M | N/D | 1968 |
Ms. Karen L. Hale | Chief Legal Officer | 2,36M | N/D | 1968 |
Dr. Robert Kowalski Pharm.D. | Chief People & Organization Officer | 2,11M | N/D | 1968 |
Etienne Jousseaume | Head of Market Access, Cell & Gene Europe | N/D | N/D | N/D |
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
L'ISS Governance QualityScore di Novartis AG al 1 maggio 2024 è 1. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 2; diritti degli azionisti: 1; retribuzione: 3.